Core Insights - Mirum Pharmaceuticals has completed enrollment in the phase III EXPAND study for Livmarli, targeting cholestatic pruritus in patients aged six months and older with rare cholestatic liver diseases, including biliary atresia [1][8] - The study aims to support potential label expansion for Livmarli, with top-line data expected in Q4 2026 [2][8] - Livmarli, an orally administered IBAT inhibitor, is currently approved for treating cholestatic pruritus in patients with Alagille syndrome and certain patients with progressive familial intrahepatic cholestasis [3][4] Company Performance - Mirum's shares have increased by 17.3% year to date, outperforming the industry average rise of 2.8% [5] - Livmarli's net product sales reached $360 million in 2025, reflecting a 68.8% year-over-year increase, driving the company's revenue growth [9] - The acquisition of Travere Therapeutics' bile acid products has diversified Mirum's revenue stream, with revenues from these products totaling $161.3 million, up 31% year over year in 2025 [10] Future Outlook - Mirum anticipates worldwide net product sales of approximately $630-$650 million in 2026, driven by strong sales of Livmarli and other marketed products [11]

Core Insights - Mirum Pharmaceuticals has completed enrollment in the phase III AZURE-1 study and screening in the AZURE-4 study for its candidate brelovitug, targeting chronic hepatitis delta virus (HDV) [1][5] - The company anticipates reporting top-line 24-week data from both studies in the second half of 2026, which will support a biologics license application (BLA) submission in 2027 [2][5] - Following the announcement, Mirum's shares fell by 5.6%, although the stock has increased by 11.2% year-to-date, outperforming the industry average of 8.1% [2] Study and Drug Development - The AZURE-1 and AZURE-4 studies are assessing a composite endpoint of virologic response and ALT normalization at 24 weeks, aligning with FDA guidelines for accelerated approval [6] - Brelovitug, a fully human monoclonal antibody, was added to Mirum's pipeline through the acquisition of Bluejay Therapeutics in January 2026, enhancing the company's focus on severe liver diseases [3] Financial Performance - Mirum's lead product, Livmarli, generated net sales of $360 million in 2025, reflecting a year-over-year increase of 68.8%, and is a significant revenue driver for the company [8] - Sales of bile acid products, including Livmarli, increased by 31% year-over-year to $161.3 million in 2025 [8] Market Position - Mirum currently holds a Zacks Rank of 3 (Hold), with other biotech stocks like ANI Pharmaceuticals, ALX Oncology, and Replimune Group rated higher [9]

Core Viewpoint - Mirum Pharmaceuticals is focused on developing therapies for rare liver diseases, with significant revenue growth driven by innovative treatments like Livmarli and bile acid drugs [1][6]. Financial Performance - Mirum reported a 50% increase in revenues for the fourth quarter, driven by strong sales of Livmarli and bile acid drugs, despite incurring a net loss [3][6]. - The company has a market capitalization of approximately $4.77 billion, indicating its size and market presence [5][6]. Stock Performance - Currently, MIRM's stock is priced at $92.22, reflecting a 15.10% decrease, with fluctuations between $90.26 and $100.19 on the trading day [4][6]. - Over the past year, the stock reached a high of $107.41 and a low of $36.88, indicating significant volatility [4]. Analyst Outlook - RBC Capital set a price target of $128 for MIRM, suggesting a potential upside of about 36% from its trading price of $94.14 at the time [2].

Core Insights - Mirum Pharmaceuticals, Inc. reported $148.93 million in revenue for Q4 2025, marking a year-over-year increase of 49.8% [1] - The earnings per share (EPS) for the same period was -$0.11, an improvement from -$0.49 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $141.27 million by 5.42%, while the EPS fell short of the consensus estimate of $0.02 by 650% [1] Financial Performance - Total product sales reached $148.93 million, slightly above the average estimate of $142.62 million from four analysts [4] - Product sales for Bile Acid Medicines were $42.55 million, closely aligning with the average estimate of $42.58 million from three analysts [4] - Livmarli product sales amounted to $106.39 million, surpassing the estimated $98.37 million from three analysts [4] Stock Performance - Shares of Mirum Pharmaceuticals have returned +8.3% over the past month, contrasting with a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Group 1 - Mirum Pharmaceuticals received approval from Health Canada for the tablet formulation of Livmarli to treat cholestatic pruritus in patients with Alagille syndrome (ALGS) [1] - Following the approval announcement, Mirum's shares increased by over 5% in pre-market trading [1] - ALGS is a rare genetic disorder that can cause cholestasis and severe itching due to bile duct abnormalities [1] Group 2 - Livmarli was previously approved in Canada as an oral solution for ALGS patients aged 12 months and older [2] - Health Canada also authorized Livmarli for treating cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC) [2] - Mirum Pharmaceuticals shares closed at $103.96 on Wednesday, reflecting a decrease of 1.41% [2]

Core Viewpoint - Mirum Pharmaceuticals is showing strong performance and growth potential, with shares more than doubling over the past year, but it is not yet consistently profitable [1][2]. Financial Performance - For the first nine months of 2025, Mirum generated $372.4 million in revenue, reflecting a year-over-year increase of 56.8% [3]. - The company reported a loss per share of $0.35 for this period, an improvement from a loss of $1.36 per share in the same period last year [3]. - In Q3 2025, Mirum achieved a net profit of $2.9 million, a significant turnaround from a net loss of $14.2 million in Q3 2024 [4]. Revenue Projections - Mirum expects to achieve $520 million in net product sales for the full 2025 fiscal year, indicating at least a 54.4% growth compared to 2024 [6]. - For 2026, the company is guiding for net sales between $630 million to $650 million, representing a midpoint growth of 23.1% compared to 2025 [6]. Strategic Acquisitions - The company recently acquired Bluejay Therapeutics for $620 million, which may negatively impact short-term profitability due to acquisition costs but is expected to enhance revenue and earnings in the long run [7]. Future Outlook - Mirum has key clinical catalysts that could positively impact its stock price and drive sales growth [8]. - Despite recent strong performance, there are concerns about limited upside potential and the timeline for achieving consistent profitability [8][9].

Core Viewpoint - Mirum Pharmaceuticals is positioned for significant growth, with its share price having more than doubled in the past year and expectations for further increases in 2026 due to key developments in its pipeline and financial performance [1]. Financial Performance - Mirum achieved positive cash flow from operations in 2025, marking a significant milestone for the company [2]. - Net product sales for Livmarli increased by 69% year over year in 2025, reaching $359 million, while sales for Cholbam and Ctexli rose by 31% to $161 million. The company anticipates overall revenue guidance of $630 million to $650 million for the current year [5]. Regulatory Approvals - The company received two FDA approvals in the previous year: Ctexli for treating cerebrotendinous xanthomatosis and a tablet formulation of Livmarli for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis [3]. Pipeline Developments - On January 26, 2026, Mirum completed the acquisition of Bluejay Therapeutics, adding brelovitug to its pipeline, which targets chronic hepatitis delta virus, a rare liver disease with no current approved treatment in the U.S. [4]. - The company is expecting results from a Phase 2B clinical study of volixibat for primary sclerosing cholangitis in the second quarter of 2026, with plans to file for accelerated approval in the second half of the year [6]. - Results from a Phase 3 study of brelovitug for HDV treatment are anticipated in the latter half of 2026, with potential filing for approval in early 2027 if results are positive [8]. - The timing of the Phase 3 study of Livmarli for pruritus in rare cholestatic conditions has been accelerated, with enrollment expected to complete in the first half of 2026 and topline data to be reported by year-end [9].

Core Insights - CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) attract investors in the rare-disease biotech sector due to smaller patient populations that can yield significant revenue through premium pricing and regulatory incentives [1] - Both companies benefit from clearer clinical endpoints and faster regulatory pathways, allowing quicker market entry compared to traditional drugs [1] CorMedix (CRMD) Overview - CorMedix's lead product, DefenCath, received FDA approval in late 2023 as the first antimicrobial catheter lock solution in the U.S., aimed at reducing catheter-related bloodstream infections in kidney failure patients [2] - DefenCath generated $167.6 million in net sales in the first nine months of 2025, indicating strong market adoption [7] - The company plans to expand DefenCath's label into total parenteral nutrition and has diversified its revenue through a $300 million acquisition of Melinta Therapeutics, adding seven approved therapies to its portfolio [7] - Despite initial success, CorMedix's future outlook is cautious, with 2026 revenue guidance of $300-$320 million and projected 2027 revenues of $100-$140 million, reflecting pricing pressures and limited growth [8][11] Mirum Pharmaceuticals (MIRM) Overview - Mirum's lead product, Livmarli, is approved for treating cholestatic pruritus in patients with Alagille syndrome and has seen a 70% year-over-year increase in net sales, reaching $161.4 million in the first nine months of 2025 [3][12] - The company has expanded its portfolio with a new tablet formulation of Livmarli and additional bile acid products from the acquisition of Travere Therapeutics, generating $118.8 million in the first nine months of 2025 [16] - MIRM's revenue guidance for 2026 is approximately $630-$650 million, supported by a broader product base and ongoing clinical studies for new therapies [16][28] Comparative Analysis - Both companies exhibit a similar risk-reward profile, but MIRM presents a clearer growth narrative with multiple revenue drivers, while CRMD's outlook is clouded by conservative guidance and reliance on a single product [4][9] - MIRM's shares have increased by 75.3% over the past six months, contrasting with CRMD's 38% decline, indicating market preference for MIRM's growth potential [23] - Valuation metrics show MIRM trading at a price/book ratio of 16.02, significantly higher than CRMD's 1.43, reflecting investor confidence in MIRM's growth prospects [24] Investment Recommendation - Mirum Pharmaceuticals is viewed as the better investment opportunity due to its strong sales growth, diversified revenue streams, and multiple growth levers, while CorMedix faces more uncertainty and competitive pressures [25][29]

Summary of Mirum Pharmaceuticals FY Conference Call Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Focus**: Rare disease company delivering life-changing medicines to patients with rare diseases - **Key Products**: Livmarli, Volixibat, Chenodal, Cholbam, Brilovatug Financial Performance - **2025 Product Revenue**: Estimated at $520 million - **2026 Revenue Guidance**: Expected between $630 million and $650 million - **Potential Revenue from Pipeline**: Over $4 billion across current commercial and pipeline programs [3][25] Key Products and Pipeline Livmarli - **Indications**: Approved for Alagille syndrome and PFIC, with a third indication expected to read out later this year - **2025 Revenue**: $359 million, with strong growth driven by pediatric patient starts and label expansion into PFIC [8][30] - **Future Potential**: Estimated billion-plus potential opportunity [6][30] - **EXPAND Study**: Aiming for label expansion into other cholestatic pruritic indications, with top-line data expected in Q4 [10][12] Volixibat - **Indications**: Studied for PSC and PBC, targeting a significant unmet need in cholestatic pruritus [12][13] - **Market Size**: Approximately 30,000 patients with PSC, with two-thirds experiencing pruritus [13] - **Upcoming Data**: Top-line data from the VISTAS study expected next quarter, with NDA filing anticipated in the second half of the year [16][25] Brilovatug (Acquisition of BlueJ Therapeutics) - **Indication**: Targeting hepatitis delta, a rare co-infection with HBV - **Market Size**: Approximately 15,000 diagnosed and insured patients in the U.S., with potential for higher prevalence in other regions [22][48] - **Phase 2 Results**: Achieved 100% virologic response, with a 65%-82% response rate on FDA approval endpoints [23][47] - **Phase 3 Program**: AZURE studies currently enrolling, with top-line data expected in the second half of the year [24][25] Market Dynamics - **Livmarli**: Strong growth driven by increased awareness and diagnosis in adult PFIC settings, with a focus on genetic testing [9][28] - **Volixibat**: Positioned as the only potential therapy for PSC, with a significant market opportunity due to the lack of approved therapies [41][42] - **PBC Market**: More competitive with recent approvals of PPARs, but still presents opportunities for IBAT inhibitors [43] Commercial Strategy - **Geographic Focus**: Direct commercialization in North America and Western Europe, with partnerships in smaller countries [5] - **Field Expansion**: Plans to increase the U.S. field force by 30-40 people to target community physicians and GI specialists [44] Risks and Considerations - **Regulatory Risks**: Ongoing monitoring of clinical trial outcomes and regulatory approvals for pipeline products [2][25] - **Market Competition**: Need to navigate competitive landscapes, especially in the PBC market [42][43] Conclusion - Mirum Pharmaceuticals is positioned for significant growth with a strong pipeline and commercial strategy, focusing on rare diseases and addressing unmet medical needs in cholestatic conditions and hepatitis delta. The company anticipates pivotal data readouts in the coming year that could further enhance its market position and revenue potential [25][26].

Group 1 - TimesSquare Capital Management's "U.S. Small Cap Growth Strategy" reported a gross return of 2.26% and a net return of 2.01% for Q3 2025, significantly underperforming the Russell 2000 Growth Index, which returned 12.19% [1] - All asset classes except fixed income outside the U.S. posted positive returns during the quarter [1] - The fund's top five holdings were highlighted as its best picks for 2025 [1] Group 2 - Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) was noted for a one-month return of 15.54% and a 52-week gain of 79.65%, with a market capitalization of $3.905 billion as of January 5, 2026 [2] - Mirum Pharmaceuticals reported revenue of $133 million in Q3 2025, reflecting a nearly 50% year-over-year increase [3] - The company is developing new applications for its flagship treatment, Livmarli, to address a third indication [3]